Cella David, Beaumont Jennifer L
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 633 N. St. Clair, 19th Floor, Chicago, IL 60611, USA.
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Ther Adv Urol. 2016 Feb;8(1):61-9. doi: 10.1177/1756287215614236.
Pazopanib is an orally available multitargeted tyrosine kinase inhibitor (a class of targeted therapies) that inhibits tumor angiogenesis and cell proliferation. The safety and efficacy of pazopanib (noninferior to sunitinib for progression-free survival) in patients with advanced or metastatic renal cell carcinoma (mRCC) have been demonstrated in several clinical trials. However, in addition to therapeutic efficacy, treatment choices should also take into account health-related quality of life (HRQoL) aspects of cancer therapy. Here, we summarize the HRQoL findings related to pazopanib use, based on patient-reported outcome measures; pazopanib has been shown to be superior to sunitinib on several HRQoL domains (including patient preference). A further consideration for treatment choice is how well the findings from clinical trials correlate with evidence from general clinical practice. This review therefore includes descriptions of real-world experience of pazopanib use in the treatment of patients with mRCC, following its approval by medical regulatory authorities in a number of countries. Naturalistic observational studies demonstrate that the efficacy of pazopanib in patients with mRCC is consistent with clinical trial findings. Similarly, consistent results were observed for the safety profile of pazopanib between observational studies and clinical trials, with most treatment-associated adverse events being mild to moderate in severity, and manageable.
帕唑帕尼是一种口服的多靶点酪氨酸激酶抑制剂（一类靶向治疗药物），可抑制肿瘤血管生成和细胞增殖。在多项临床试验中已证实帕唑帕尼（在无进展生存期方面不劣于舒尼替尼）用于晚期或转移性肾细胞癌（mRCC）患者的安全性和有效性。然而，除了治疗效果外，治疗选择还应考虑癌症治疗中与健康相关的生活质量（HRQoL）方面。在此，我们基于患者报告的结局指标总结与使用帕唑帕尼相关的HRQoL研究结果；帕唑帕尼在多个HRQoL领域（包括患者偏好）已被证明优于舒尼替尼。治疗选择的另一个考虑因素是临床试验结果与一般临床实践证据的相关性如何。因此，本综述包括在多个国家的医学监管机构批准后，帕唑帕尼用于治疗mRCC患者的真实世界经验描述。自然观察性研究表明，帕唑帕尼在mRCC患者中的疗效与临床试验结果一致。同样，在观察性研究和临床试验之间，帕唑帕尼的安全性概况也观察到了一致的结果，大多数与治疗相关的不良事件严重程度为轻度至中度，且易于管理。
